Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coagulopathy Clear all
Active, not recruiting No phase listed Observational

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

NCT04628871
View directory record Official record
Conditions
Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II
Interventions
SB-318, SB-913, SB-FIX
Biological
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
5
States / cities
Oakland, California • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

IGIV Study for Chronic ITP Patients Ages 3-70

NCT00511147
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
IGIV3I Grifols 10%
Biological
Lead sponsor
Grifols Biologicals, LLC
Industry
Eligibility
3 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

NCT01138501
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Phoenix, Arizona • Orange, California • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00504075
View directory record Official record
Conditions
Chronic Idiopathic Thrombocytopenic Purpura
Interventions
Gammaplex, intravenous immunoglobulin
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Orange City, Florida • Chicago, Illinois • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Jul 21, 2026, 6:09 PM EDT
Completed No phase listed Observational

ATHN 11: Liver Transplantation Outcomes Study

NCT04055051
View directory record Official record
Conditions
Hemophilia A and B, Liver Transplantation
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Peoria, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus for Autoimmune Disease of Blood Cells

NCT00392951
View directory record Official record
Conditions
Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune, Autoimmune Neutropenia, Lupus Erythematosus, Systemic, Inflammatory Bowel Disease, Rheumatoid Arthritis
Interventions
sirolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

NCT00543439
View directory record Official record
Conditions
Hemophilia A
Interventions
Moroctocog alfa (AF-CC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Months to 15 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
7
States / cities
Cincinnati, Ohio • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Jul 21, 2026, 6:09 PM EDT
Completed No phase listed Observational

Trends in Transfusion Strategies and Outcomes in Trauma

NCT07603999
View directory record Official record
Conditions
Transfusion, Trauma Coagulopathy, Mortality, Blood Transfusion
Interventions
Not listed
Lead sponsor
Mariah Arif
Government
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

NCT01563445
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
activated recombinant human factor VII, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jul 21, 2026, 6:09 PM EDT
Completed No phase listed Observational

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood

NCT04401436
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 21, 2026, 6:09 PM EDT
Enrolling by invitation No phase listed Observational

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

NCT05962398
View directory record Official record
Conditions
Hemophilia B
Interventions
AAV5-hFIXco-Padua
Genetic
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

THC Crossover Study

NCT04429568
View directory record Official record
Conditions
THC, Cannabis, Cannabis Smoking, Cannabis Use, Unspecified, Cigarette Smoking, Tobacco Use, Nicotine Dependence, Nicotine Withdrawal, Cardiovascular Risk Factor
Interventions
Smoked Cannabis, Vaped Cannabis, Tobacco Cigarette
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Jul 21, 2026, 6:09 PM EDT
Completed No phase listed Observational

Chronology of Occult and Gross Coagulopathy in Burn Patients

NCT01638481
View directory record Official record
Conditions
Thermal Burns
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

NCT03569891
View directory record Official record
Conditions
Hemophilia B
Interventions
AAV5-hFIXco-Padua, Factor IX (FIX)
Genetic · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older · Male only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 21, 2026, 6:09 PM EDT
Completed No phase listed Observational

Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery

NCT03161626
View directory record Official record
Conditions
Factor 10 Deficiency
Interventions
Coagadex
Drug
Lead sponsor
Bio Products Laboratory
Other
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Gainesville, Florida • New Orleans, Louisiana • Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02076399
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Fostamatinib disodium, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease

NCT00010387
View directory record Official record
Conditions
Anemia, Hemolytic, Autoimmune, Felty Syndrome, Purpura, Thrombocytopenic, Autoimmune Diseases
Interventions
cyclophosphamide, filgrastim
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

NCT00079716
View directory record Official record
Conditions
Multiple Myeloma
Interventions
SGN-40 (anti-huCD40 mAb)
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
5
States / cities
West Hollywood, California • Denver, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Jul 21, 2026, 6:09 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of Pirfenidone Treatment in HPS-ILD

NCT04193592
View directory record Official record
Conditions
Hermansky Pudlak Syndrome, Interstitial Lung Disease
Interventions
Pirfenidone
Drug
Lead sponsor
Jesse Roman
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Jul 21, 2026, 6:09 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

NCT00909363
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding
Interventions
Promacta, blood drawing in patients with WAS, blood drawing in healthy controls
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
3 Months to 80 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

NCT01493778
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 6 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Long Beach, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2020 · Synced Jul 21, 2026, 6:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

NCT05987449
View directory record Official record
Conditions
Hemophilia A
Interventions
NXT007
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 59 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
4
States / cities
Sacramento, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

NCT01712438
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Human cl rhFVIII
Biological
Lead sponsor
Octapharma
Industry
Eligibility
Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Sacramento, California • St. Petersburg, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Jul 21, 2026, 6:09 PM EDT
Completed Phase 4 Interventional Results available

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

NCT01289847
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinemia, Hyper-IgM Syndrome, Wiskott-Aldrich Syndrome
Interventions
Gammaplex
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
2 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Irvine, California • Los Angeles, California • Centennial, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Jul 21, 2026, 6:09 PM EDT